Literature DB >> 19034673

Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells.

Padmaja Magadala1, Mansoor Amiji.   

Abstract

Type B gelatin-based engineered nanocarrier systems (GENS) have been used over the last several years as a non-condensing systemic and oral DNA delivery system. In this study, we have modified the surface of GENS with epidermal growth factor receptor (EGFR)-targeting peptide for gene delivery and transfection in pancreatic cancer cell lines. GENS were prepared by the solvent displacement method and the EGFR-targeting peptide was grafted on the surface using a hetero-bifunctional poly(ethylene glycol) (PEG) spacer. Plasmid DNA, encoding for enhanced green fluorescent protein (GFP), was efficiently encapsulated and protected from degrading enzymes in the control and surface-modified GENS. Upon incubation with EGFR over-expressing Panc-1 human pancreatic adenocarcinoma cells, the peptide-modified nanoparticles were found to be internalized efficiently by receptor-mediated endocytosis. Both quantitative and qualitative transgene expression efficiencies were significantly enhanced when plasmid DNA was administered with EGFR-targeted GENS relative to the control-unmodified gelatin or PEG-modified gelatin nanoparticle systems. Based on these preliminary results, EGFR-targeted GENS show tremendous promise as a safe and effective gene delivery vector with the potential to treat pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034673      PMCID: PMC2628214          DOI: 10.1208/s12248-008-9065-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  37 in total

Review 1.  Gene replacement strategies for lung cancer.

Authors:  J A Roth
Journal:  Curr Opin Oncol       Date:  1998-03       Impact factor: 3.645

Review 2.  Gene therapy strategies for treating neoplastic disease.

Authors:  B E Huber
Journal:  Ann N Y Acad Sci       Date:  1994-05-31       Impact factor: 5.691

3.  Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione.

Authors:  Sushma Kommareddy; Mansoor Amiji
Journal:  Bioconjug Chem       Date:  2005 Nov-Dec       Impact factor: 4.774

4.  Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.

Authors:  Zonghai Li; Ruijiao Zhao; Xianghua Wu; Ye Sun; Ming Yao; Jinjun Li; Yuhong Xu; Jianren Gu
Journal:  FASEB J       Date:  2005-12       Impact factor: 5.191

5.  Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies.

Authors:  Goldie Kaul; Mansoor Amiji
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

6.  HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.

Authors:  Veronique Guillemard; Hinyu N Nedev; Alan Berezov; Ramachandran Murali; H Uri Saragovi
Journal:  DNA Cell Biol       Date:  2005-06       Impact factor: 3.311

7.  Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model.

Authors:  Goldie Kaul; Mansoor Amiji
Journal:  J Drug Target       Date:  2004       Impact factor: 5.121

8.  Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter.

Authors:  Dietmar Jacob; John J Davis; Lidong Zhang; Hongbo Zhu; Fuminori Teraishi; Bingliang Fang
Journal:  Cancer Gene Ther       Date:  2005-02       Impact factor: 5.987

Review 9.  Gene therapy and pancreatic cancer.

Authors:  A S Pearson; M Bouvet; D B Evans; J A Roth
Journal:  Front Biosci       Date:  1998-11-01

Review 10.  Gene replacement strategies for cancer.

Authors:  J A Roth
Journal:  Isr J Med Sci       Date:  1996-02
View more
  13 in total

1.  Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene delivery.

Authors:  Husain Attarwala; Mansoor Amiji
Journal:  Pharm Res       Date:  2012-01-27       Impact factor: 4.200

2.  Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice.

Authors:  Jing Xu; Florence Gattacceca; Mansoor Amiji
Journal:  Mol Pharm       Date:  2013-04-16       Impact factor: 4.939

Review 3.  Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery.

Authors:  Jing Xu; Shanthi Ganesh; Mansoor Amiji
Journal:  Int J Pharm       Date:  2011-05-19       Impact factor: 5.875

4.  Polydopamine-enabled surface functionalization of gold nanorods for cancer cell-targeted imaging and photothermal therapy.

Authors:  Kvar C L Black; Ji Yi; José G Rivera; Daria C Zelasko-Leon; Phillip B Messersmith
Journal:  Nanomedicine (Lond)       Date:  2012-08-14       Impact factor: 5.307

5.  An epidermal growth factor motif from Del1 protein increases the efficiency of in vivo gene transfer with a non-viral vector.

Authors:  Atsushi Mamiya; Hisataka Kitano; Kyoichi Takao; Shinichiro Kokubun; Masamichi Komiya; Chiaki Hidai
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

6.  Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells.

Authors:  Meghna Talekar; Srinivas Ganta; Amit Singh; Mansoor Amiji; Jackie Kendall; William A Denny; Sanjay Garg
Journal:  Pharm Res       Date:  2012-06-01       Impact factor: 4.200

Review 7.  EGF receptor-targeted nanocarriers for enhanced cancer treatment.

Authors:  Alyssa M Master; Anirban Sen Gupta
Journal:  Nanomedicine (Lond)       Date:  2012-12       Impact factor: 5.307

Review 8.  Gelatin carriers for drug and cell delivery in tissue engineering.

Authors:  Marco Santoro; Alexander M Tatara; Antonios G Mikos
Journal:  J Control Release       Date:  2014-04-16       Impact factor: 9.776

Review 9.  Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Authors:  Richard Callaghan; Frederick Luk; Mary Bebawy
Journal:  Drug Metab Dispos       Date:  2014-02-03       Impact factor: 3.922

10.  Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis.

Authors:  Srujan Kumar Gandham; Meghna Talekar; Amit Singh; Mansoor M Amiji
Journal:  Int J Nanomedicine       Date:  2015-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.